|
|
|
The company’s active Scientific Advisory Board is comprised of global leaders in biochemistry, organic and inorganic chemistry, cardiology, radiation oncology, nuclear medicine and radiology. This team includes:
|
William C. Eckelman, Ph.D.
|
Chair, Scientific Advisory Board,
Molecular Insight Pharmaceuticals, Inc.
Former Chief of Positron Emission Tomography (PET) Department,
National Institutes of Health (NIH)
|
| |
|
|
Ronald L. Van Heertum, M.D.
|
Professor of Radiology, Vice Chairman of Professional Regulatory
Affairs, Director of the Division of Nuclear Medicine and Director
of the Morton A. Kreitchman PET Center Medicine,
Columbia University College of Physicians & Surgeons
|
| |
|
|
Ross J. Baldessarini, M.D.
|
Director, Neuropharmacology Laboratory, McLean Hospital
Professor of Neuroscience in Psychiatry, Harvard Medical School
|
| |
|
|
Peter Conti, M.D., Ph.D.
|
Professor of Radiology, Biomedical Engineering, and Pharmacy,
University of Southern California
|
| |
|
|
Alan Davison, Ph.D., F.R.S.
|
Professor of Chemistry,
Massachusetts Institute of Technology
|
| |
|
|
Duncan H. Hunter, Ph.D.
|
Professor and Associate Dean of Science,
University of Western Ontario
|
| |
|
|
Alan P. Kozikowski, Ph.D.
|
Professor and Head, Department of Medicinal Chemistry and
Pharmacognosy, University of Illinois at Chicago
|
| |
|
|
Rob Mairs, Ph.D.
|
Head of Pediatric Oncology, Cancer Research UK Beatson Laboratories,
University of Glasgow
|
| |
|
|
H. William Strauss, M.D.
|
Clinical Director, Nuclear Medicine Service,
Memorial Sloan-Kettering Cancer Center
|
| |
|
|
Vladimir Torchilin, Ph.D.
|
Professor and Chairman, Pharmaceutical Chemistry,
Northeastern University
|
| |
|
|
John F. Valliant, Ph.D.
|
Associate Professor of Chemistry, McMaster University
|
| |
|
|
Barry Zarett, M.D.
|
Chief, Section of Cardiovascular Medicine,
Yale University School of Medicine
|
| |
|
|
Jon A. Zubieta, Ph.D.
|
Distinguished Professor of Chemistry, Syracuse University
|
| |
|
|
|